Sotera Health (NASDAQ:SHC) Given Average Rating of “Moderate Buy” by Brokerages

Sotera Health (NASDAQ:SHC) has been given an average rating of “Moderate Buy” by the seven research firms that are presently covering the company, Marketbeat reports. Three analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $16.08.

A number of equities research analysts recently weighed in on SHC shares. The Goldman Sachs Group assumed coverage on Sotera Health in a research note on Friday. They set a “neutral” rating and a $14.00 price objective for the company. Citigroup boosted their target price on shares of Sotera Health from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $17.00 price target on shares of Sotera Health in a report on Thursday, November 21st.

Sotera Health Stock Performance

Sotera Health stock opened at $13.13 on Monday. The company has a debt-to-equity ratio of 4.91, a quick ratio of 2.61 and a current ratio of 2.88. The company has a market capitalization of $3.72 billion, a PE ratio of 52.52 and a beta of 1.96. The company has a 50 day moving average price of $14.89 and a 200-day moving average price of $14.11. Sotera Health has a fifty-two week low of $10.71 and a fifty-two week high of $17.44.

Sotera Health (NASDAQ:SHC) last issued its earnings results on Tuesday, November 5th. The company reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). Sotera Health had a net margin of 6.31% and a return on equity of 42.27%. The firm had revenue of $285.47 million for the quarter, compared to the consensus estimate of $278.64 million. During the same period last year, the firm earned $0.18 earnings per share. The company’s revenue for the quarter was up 8.5% on a year-over-year basis. As a group, equities analysts forecast that Sotera Health will post 0.61 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. CWM LLC raised its position in Sotera Health by 86.1% in the second quarter. CWM LLC now owns 2,146 shares of the company’s stock valued at $25,000 after purchasing an additional 993 shares during the period. True Wealth Design LLC acquired a new position in shares of Sotera Health in the third quarter worth $32,000. GAMMA Investing LLC increased its holdings in Sotera Health by 125.0% during the 3rd quarter. GAMMA Investing LLC now owns 2,988 shares of the company’s stock worth $50,000 after purchasing an additional 1,660 shares during the period. Point72 DIFC Ltd increased its stake in shares of Sotera Health by 556.6% during the second quarter. Point72 DIFC Ltd now owns 6,540 shares of the company’s stock worth $78,000 after buying an additional 5,544 shares during the period. Finally, Capital Performance Advisors LLP purchased a new stake in shares of Sotera Health in the 3rd quarter valued at approximately $91,000. Hedge funds and other institutional investors own 91.03% of the company’s stock.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.